Kirkland Represents Neautus on its Hong Kong IPO

Kirkland & Ellis advised Sichuan Neautus Traditional Chinese Medicine Co., Ltd. (Neautus, HKEX: 2206) on its global offering and listing on the Main Board of The Stock Exchange of Hong Kong Limited on November 11, 2026. The joint sponsors are GF Capital (Hong Kong) Limited and ABCI Capital Limited.

Neautus, a large-scale traditional Chinese medicine (TCM) decoction-ready products provider in China, raised approximately HK$262 million by offering 6,517,300 H Shares at a price of HK$40.20 per H Share, with the Hong Kong public offering tranche oversubscribed by 2,190.99 times.

Neautus ranks second in China in terms of revenue from TCM decoction-ready products in 2025, according to Frost & Sullivan. Its footprint also extends across most of the provinces in Chinese Mainland, as well as Hong Kong, Taiwan, and overseas in regions with strong TCM demand, such as Vietnam and Malaysia.

The Kirkland team included capital markets lawyers Dr. Mengyu Lu, Brian Ho, Ashlee Wu, Yuchen Han, Sierra Tao, Bill Feng, Rock Liu and Chuanwen Wang.